The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Neoadjuvant epacadostat with short course radiotherapy in pts with locally advanced rectal cancer
Moh’d Khushman, MD, Washington University, St. Louis, MO, discusses findings from a Phase II study evaluating neoadjuvant epacadostat combined with short course radiotherapy in patients with locally advanced rectal cancer. Favorable safety was observed, and promising activity in the small cohort of patients enrolled. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
